Palbociclib Does Not Improve PFS After Progression on CDK4/6 Inhibitors, ET

Continuing CDK4/6 inhibitor therapy and switching ET after progression does not improve PFS vs switching ET alone in HR+, HER2- metastatic breast cancer.

Related Keywords

Boston , Massachusetts , United States , San Antonio , Texas , Dana Farber Cancer Institute , Erical Mayer , , San Antonio Breast Cancer Symposium ,